Primary and secondary immune thrombocytopenia (ITP): Time for a rethink

Cines, 2009, The ITP syndrome: pathogenic and clinical diversity, Blood, 113, 6511, 10.1182/blood-2009-01-129155 Teachey, 2012, New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome, Curr Opin Pediatr, 24, 1, 10.1097/MOP.0b013e32834ea739 Moulis, 2014, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, 124, 3308, 10.1182/blood-2014-05-578336 Gernsheimer, 1989, Mechanisms of response to treatment in autoimmune thrombocytopenic purpura, N Engl J Med, 320, 974, 10.1056/NEJM198904133201505 Semple, 2020, An update on the pathophysiology of immune thrombocytopenia, Curr Opin Hematol, 27, 423, 10.1097/MOH.0000000000000612 Zufferey, 2017, Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP), J Clin Med, 6, 10.3390/jcm6020016 Provan, 2019, Updated international consensus report on the investigation and management of primary immune thrombocytopenia, Blood Adv, 3, 3780, 10.1182/bloodadvances.2019000812 Neunert, 2019, American society of hematology 2019 guidelines for immune thrombocytopenia, Blood Adv, 3, 3829, 10.1182/bloodadvances.2019000966 Mithoowani, 2016, High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis, Lancet Haematol, 3, 10.1016/S2352-3026(16)30109-0 Gaines, 2000, Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients, Blood, 95, 2523, 10.1182/blood.V95.8.2523 Bradbury, 2021, Mycophenolate mofetil for first-line treatment of immune thrombocytopenia, N Engl J Med, 385, 885, 10.1056/NEJMoa2100596 Roumier, 2021, High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia, Am J Hematol, 96, 10.1002/ajh.26040 Zaja, 2016, Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study, Am J Hematol, 91, E293, 10.1002/ajh.24341 Al-Samkari, 2018, Romiplostim for the management of perioperative thrombocytopenia, Br J Haematol, 182, 106, 10.1111/bjh.15280 Arnold, 2019, Peri-operative eltrombopag or immune globulin for patients with immune thrombocytopaenia (the bridging ITP trial): methods and rationale, Thromb Haemost, 119, 500, 10.1055/s-0038-1677531 Schifferli, 2016, Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?, Semin Hematol, 53, S31, 10.1053/j.seminhematol.2016.04.010 Kapur, 2020, Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP), Platelets, 31, 399, 10.1080/09537104.2019.1624709 Gibiansky, 2011, Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura, J Clin Pharmacol, 51, 842, 10.1177/0091270010375427 Hayes, 2011, Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing, J Clin Pharmacol, 51, 1403, 10.1177/0091270010383019 Kuter, 2013, The biology of thrombopoietin and thrombopoietin receptor agonists, Int J Hematol, 98, 10, 10.1007/s12185-013-1382-0 Erickson-Miller, 2005, Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist, Exp Hematol, 33, 85, 10.1016/j.exphem.2004.09.006 Stasi, 2007, Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura, Blood, 110, 2924, 10.1182/blood-2007-02-068999 U.S. Food and Drug Administration Erhardt, 2009, Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function, Exp Hematol, 37, 1030, 10.1016/j.exphem.2009.06.011 Cheng, 2012, Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile, Ther Adv Hematol, 3, 155, 10.1177/2040620712442525 Chagraoui, 2002, Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice, Blood, 100, 3495, 10.1182/blood-2002-04-1133 Kuter, 2009, Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim, Blood, 114, 3748, 10.1182/blood-2009-05-224766 Fukushima-Shintani, 2009, AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist, Eur J Haematol, 82, 247, 10.1111/j.1600-0609.2008.01198.x Desjardins, 2006 Bussel, 2014, A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia, Blood, 123, 3887, 10.1182/blood-2013-07-514398 Al-Samkari, 2022, Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study, Br J Haematol, 197, 359, 10.1111/bjh.18081 Al-Samkari, 2022, Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension, Platelets, 33, 257, 10.1080/09537104.2021.1881952 Jurczak, 2018, Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia, Br J Haematol, 183, 479, 10.1111/bjh.15573 Wang, 2004, Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand, Clin Pharmacol Ther, 76, 628, 10.1016/j.clpt.2004.08.010 Bussel, 2006, AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP, N Engl J Med, 355, 1672, 10.1056/NEJMoa054626 Newland, 2006, An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura, Br J Haematol, 135, 547, 10.1111/j.1365-2141.2006.06339.x Molineux, 2010, Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside, Br J Haematol, 150, 9 Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155 Gernsheimer, 2010, Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP), J Thromb Haemost, 8, 1372, 10.1111/j.1538-7836.2010.03830.x Stasi, 2012, Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care, Int J Hematol, 96, 26, 10.1007/s12185-012-1088-8 Kuter, 2013, Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy, Br J Haematol, 161, 411, 10.1111/bjh.12260 Park, 2016, Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia, Int J Hematol, 103, 44, 10.1007/s12185-015-1889-7 Cines, 2017, Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia, Haematologica, 102, 1342, 10.3324/haematol.2016.161968 Janssens, 2015, Romiplostim treatment in adults with immune thrombocytopenia of varying duration and severity, Acta Haematol, 134, 215, 10.1159/000381657 Bussel, 2009, Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP, Blood, 113, 2161, 10.1182/blood-2008-04-150078 Cines, 2015, Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim, Int J Hematol, 102, 259, 10.1007/s12185-015-1837-6 Janssens, 2016, Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia, Ann Hematol, 95, 1077, 10.1007/s00277-016-2682-2 Bussel, 2019, Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program, Am J Hematol, 94, 546, 10.1002/ajh.25444 Patel, 2012, Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia, Blood, 119, 5989, 10.1182/blood-2011-11-393975 Duxbury, 2013, Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis, Lupus, 22, 1489, 10.1177/0961203313509295 Provan, 2007, Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults, Haematologica, 92, 1695, 10.3324/haematol.11709 Arnold, 2007, Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura, Ann Intern Med, 146, 25, 10.7326/0003-4819-146-1-200701020-00006 Hasan, 2009, Repeated courses of rituximab in chronic ITP: three different regimens, Am J Hematol, 84, 661, 10.1002/ajh.21512 Ghanima, 2015, Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 385, 1653, 10.1016/S0140-6736(14)61495-1 Arnold, 2012, A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia, Blood, 119, 1356, 10.1182/blood-2011-08-374777 Hammond, 2019, Sequence of splenectomy and rituximab for the treatment of steroid-refractory immune thrombocytopenia: does it matter?, Mayo Clin Proc, 94, 2199, 10.1016/j.mayocp.2019.05.024 Rodeghiero, 2018, A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP, Br J Haematol, 181, 183, 10.1111/bjh.15090 Mageau, 2022, Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment, Am J Hematol, 97, 10, 10.1002/ajh.26378 Dolan, 2008, Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century, Am J Hematol, 83, 93, 10.1002/ajh.21029 Togasaki, 2018, Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia, Ann Hematol, 97, 655, 10.1007/s00277-018-3232-x Rodeghiero, 2009, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, 113, 2386, 10.1182/blood-2008-07-162503 Cines, 2002, Immune thrombocytopenic purpura, N Engl J Med, 346, 995, 10.1056/NEJMra010501 Levy, 2002, High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura, Br J Haematol, 118, 836, 10.1046/j.1365-2141.2002.03709.x Zhang, 2020, Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia, Haematologica, 105, 10.3324/haematol.2019.226688 Thai, 2018, BAFF and CD4(+) T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context, Blood, 131, 1545, 10.1182/blood-2017-06-789578 Bussel, 2018, Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials, Am J Hematol, 93, 921, 10.1002/ajh.25125 Zeng, 2012, Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbα antibodies, Am J Hematol, 87, 206, 10.1002/ajh.22211 Arnold, 2017, Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP registry, Blood Adv, 1, 2414, 10.1182/bloodadvances.2017010942 Greenberg, 2022, NCCN guidelines® insights: myelodysplastic syndromes, version 3.2022, J Natl Compr Canc Netw, 20, 106, 10.6004/jnccn.2022.0009 Moore, 2022 Balduini, 2013, Inherited thrombocytopenias frequently diagnosed in adults, J Thromb Haemost, 11, 1006, 10.1111/jth.12196 Mitta, 2019, Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data, Am J Hematol, 94, E76 Miltiadous, 2020, Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment, Blood, 135, 472, 10.1182/blood.2019003599 Shah, 2014, Autoimmune lymphoproliferative syndrome: an update and review of the literature, Curr Allergy Asthma Rep, 14, 462, 10.1007/s11882-014-0462-4 Cuker, 2016, How I treat refractory immune thrombocytopenia, Blood, 128, 1547, 10.1182/blood-2016-03-603365 Chang, 2018, Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment, Eur J Haematol, 101, 549, 10.1111/ejh.13144 Reiner, 1995, Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura, Blood, 85, 351, 10.1182/blood.V85.2.351.351 Wang, 2019, Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura, Exp Ther Med, 17, 2137 Liu, 2016, Cyclosporin A for persistent or chronic immune thrombocytopenia in children, Ann Hematol, 95, 1881, 10.1007/s00277-016-2791-y Almagro, 1985, Danazol in idiopathic thrombocytopenic purpura, Acta Haematol, 74, 120, 10.1159/000206184 Estève, 2017, Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: a retrospective study of 42 patients, PloS One, 12, 10.1371/journal.pone.0187296 Taylor, 2015, Mycophenolate mofetil therapy for severe immune thrombocytopenia, Br J Haematol, 171, 625, 10.1111/bjh.13622 Fenaux, 1990, Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases, Blut, 60, 238, 10.1007/BF01728791 Park, 2016, Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study, Int J Hematol, 103, 180, 10.1007/s12185-015-1903-0 Samson, 2019, Treatments for primary immune thrombocytopenia: a review, Cureus, 11 Terrell, 2020, Immune thrombocytopenia (ITP): current limitations in patient management, Medicina (Kaunas), 56 Zhou, 2015, A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP, Blood, 125, 1541, 10.1182/blood-2014-06-581868 Choi, 2015, A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4), Blood, 126, 500, 10.1182/blood-2015-03-631937 Arnold, 2010, Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura, Blood, 115, 29, 10.1182/blood-2009-06-222448 Wang, 2012, A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia, Int J Hematol, 96, 222, 10.1007/s12185-012-1124-8 Feng, 2017, Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial, Lancet Haematol, 4, 10.1016/S2352-3026(17)30170-9 Kuter, 2022, Novel therapies for immune thrombocytopenia, Br J Haematol, 196, 1311, 10.1111/bjh.17872 He, 2022, The mechanistic effects and clinical applications of various derived mesenchymal stem cells in immune thrombocytopenia, Acta Haematol, 145, 9, 10.1159/000517989 Moulis, 2014, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, 124, 3308, 10.1182/blood-2014-05-578336 Garrido, 2014, Avances en el conocimiento y manejo del síndrome linfoproliferativo autoinmune, Anales de Pediatría, 80 Fanouriakis, 2021, Update οn the diagnosis and management of systemic lupus erythematosus, Ann Rheum Dis, 80, 14, 10.1136/annrheumdis-2020-218272 Kado, 2019, Treatment of primary and secondary immune thrombocytopenia, Curr Opin Rheumatol, 31, 213, 10.1097/BOR.0000000000000599 Fanouriakis, 2019, 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus, Ann Rheum Dis, 78, 736, 10.1136/annrheumdis-2019-215089 Velo-García, 2016, The diagnosis and management of the haematologic manifestations of lupus, J Autoimmun, 74, 139, 10.1016/j.jaut.2016.07.001 Galanopoulos, 2017, Lupus thrombocytopenia: pathogenesis and therapeutic implications, Mediterr J Rheumatol, 28, 20, 10.31138/mjr.28.1.20 Blair, 2018, Belimumab: a review in systemic lupus erythematosus, Drugs, 78, 355, 10.1007/s40265-018-0872-z Mahévas, 2021, Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial, Haematologica, 106, 2449, 10.3324/haematol.2020.259481 Abreu, 2015, The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features, Autoimmun Rev, 14, 401, 10.1016/j.autrev.2015.01.002 Sciascia, 2017, Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances, Nat Rev Rheumatol, 13, 548, 10.1038/nrrheum.2017.124 Artim-Esen, 2015, The significance and management of thrombocytopenia in antiphospholipid syndrome, Curr Rheumatol Rep, 17, 14, 10.1007/s11926-014-0494-8 Tomasello, 2021, Immune thrombocytopenia in antiphospholipid syndrome: is it primary or secondary?, Biomedicines, 9, 10.3390/biomedicines9091170 Seidel, 2019, The European society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity, J Allergy Clin Immunol Pract, 7, 1763, 10.1016/j.jaip.2019.02.004 Podjasek, 2012, Autoimmune cytopenias in common variable immunodeficiency, Front Immunol, 3, 189, 10.3389/fimmu.2012.00189 Durani, 2018, Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review, Clin Adv Hematol Oncol, 16, 670 Barcellini, 2021, Autoimmune complications in hematologic neoplasms, Cancers (Basel), 13, 10.3390/cancers13071532 Cines, 2009, Pathobiology of secondary immune thrombocytopenia, Semin Hematol, 46, S2, 10.1053/j.seminhematol.2008.12.005 Michniacki, 2019, Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies, Curr Oncol Rep, 21, 87, 10.1007/s11912-019-0838-7 Zhou, 2010, The role of B cell-activating factor secreted by peripheral blood monocyte-derived dendritic cell in chronic idiopathic thrombocytopenic purpura, Zhonghua Xue Ye Xue Za Zhi, 31, 599 Zehnder, 1995, Involvement of CD31 in lymphocyte-mediated immune responses: importance of the membrane-proximal immunoglobulin domain and identification of an inhibiting CD31 peptide, Blood, 85, 1282, 10.1182/blood.V85.5.1282.bloodjournal8551282 Afdhal, 2012, Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia, N Engl J Med, 367, 716, 10.1056/NEJMoa1110709 Galli, 2014, Thrombosis associated with viral hepatitis, J Clin Transl Hepatol, 2, 234 Kowalczyk, 2015, Initial experience with the use of thrombopoetin receptor agonists in patients with refractory HIV-associated immune thrombocytopenic purpura: a case series, J Int Assoc Provid AIDS Care, 14, 211, 10.1177/2325957414557266 Bhattacharjee, 2020, Immune thrombocytopenia secondary to COVID-19: a systematic review, SN Compr Clin Med, 2, 2048, 10.1007/s42399-020-00521-8 Schaefers, 2023, Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - a monocentric analysis, Br J Haematol, 201, 222, 10.1111/bjh.18686 Pavord, 2020, Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic, Br J Haematol, 189, 1038, 10.1111/bjh.16775 Arnold, 2009, Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review, Haematologica, 94, 850, 10.3324/haematol.2008.005348 Frydman, 2015, Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography, Helicobacter, 20, 239, 10.1111/hel.12200 Chey, 2017, ACG clinical guideline: treatment of Helicobacter pylori infection, Am J Gastroenterol, 112, 212, 10.1038/ajg.2016.563 Danese, 2020, Drug-induced thrombocytopenia: mechanisms and laboratory diagnostics, Semin Thromb Hemost, 46, 264, 10.1055/s-0039-1697930 Platelets on the Web Mitta, 2019, Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data, Am J Hematol, 94 George, 2009, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management, Hematology Am Soc Hematol Educ Program, 153, 10.1182/asheducation-2009.1.153 Arepally, 2020, Pathogenesis of heparin-induced thrombocytopenia, Transl Res, 225, 131, 10.1016/j.trsl.2020.04.014 Lee, 2013, Heparin-induced thrombocytopenia, Hematology Am Soc Hematol Educ Program, 2013, 668, 10.1182/asheducation-2013.1.668 Bailly, 2021, Heparin-induced thrombocytopenia: an update for the COVID-19 era, S Afr Med J, 111, 841, 10.7196/SAMJ.2021.v111i9.15909 Wraith, 2003, Vaccination and autoimmune disease: what is the evidence?, Lancet, 362, 1659, 10.1016/S0140-6736(03)14802-7 Di Pietrantonj, 2021, Vaccines for measles, mumps, rubella, and varicella in children, Cochrane Database Syst Rev, 11 Shlamovitz, 2013, A case of Evans’ syndrome following influenza vaccine, J Emerg Med, 44, e149, 10.1016/j.jemermed.2012.01.060 Lee, 2021, Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination, Am J Hematol, 96, 534, 10.1002/ajh.26132 Lee, 2022, SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP, Blood, 139, 1564, 10.1182/blood.2021013411 Lambert, 2017, Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia, Am J Hematol, 92, E88, 10.1002/ajh.24705 Alvarez Román, 2014, Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia, Thromb Haemost, 112, 65, 10.1160/TH13-10-0873 González-López, 2022, Proposal for a new protocol for the management of immune thrombocytopenia (ITP), Adv Ther, 39, 2287, 10.1007/s12325-022-02133-1 González-López, 2023, Current concepts in the diagnosis and management of adult primary immune thrombocytopenia: our personal view, Medicina (Kaunas), 59